Most of the investigations for an alternative medicinal treatment on
atherosclerosis have been focused on natural or dietary compounds including
phytochemicals. So far, few studies regarding anti-atherosclerotic small
peptides except for tetrapeptide of Lys-
Arg-Glu-Ser have been reported. The present study was, thus, to investigate whether
dipeptide Trp-His, which is one of vasodilating small
peptides, could reduce atherosclerotic lesions in
apo E-deficient mice fed a high-fat diet. The animal study involved a 9-week-successive administration of
Trp-His at a dose of 0, 10 or 100 mg/kg per d. After 9-week administration, en face analyses provided the first direct evidence that the atherosclerotic lesion area was significantly reduced by 27 and 38 % for
Trp-His dosed
at 10 and 100 mg/kg per d, respectively, compared with the control group. Administration of
Trp-His did not affect growth parameters such as
body weight and feeding efficiency (P>0.1). Total serum
cholesterol and
HDL-cholesterol as well as
lipid profiles in the liver did not differ between the tested groups. Taken together, the anti-atherosclerotic effect of
dipeptide Trp-His should be addressed into physiological functions of bioactive
peptides, in which the
dipeptide may elicit the power by alternative mechanism(s), not by the regulation of lipid metabolism.